N‑Myc induces the tumor progression of prostate cancer by regulating FSCN1

He,Guifang; Li,Mingfeng; Fang,Linna; Xu,Lingfan; Huang,Xiaojuan; Zheng,Lulu; Yang,Lijie; Luo,Wenwu; Cai,Yongping; Ma,Wei; Liang,Chaozhao; Yin,Yu

doi:10.3892/or.2020.7775

N‑Myc induces the tumor progression of prostate cancer by regulating FSCN1

Authors:
- Guifang He
- Mingfeng Li
- Linna Fang
- Lingfan Xu
- Xiaojuan Huang
- Lulu Zheng
- Lijie Yang
- Wenwu Luo
- Yongping Cai
- Wei Ma
- Chaozhao Liang
- Yu Yin
View Affiliations

Affiliations: Department of Pathology, Anhui Medical University, Hefei, Anhui 230032, P.R. China, Department of Urology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Department of Pathology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
Published online on: September 22, 2020 https://doi.org/10.3892/or.2020.7775
Pages: 2265-2274

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The oncoprotein N‑Myc has a carcinogenic effect in numerous types of cancer, and it can cause castration resistance in prostate cancer (PCa), and leads to the development of small cell neuroendocrine cancer by regulating multiple target genes. Immunohistochemical staining, RT‑qPCR, western blotting, wound healing and CCK‑8 assays were used to detect the expression of N‑Myc and FSCN1 as well as AR and CgA at the human level and cell level. The immunohistochemical results revealed that the protein levels of N‑Myc proto‑oncogene protein (N‑Myc) and fascin (FSCN1) in PCa were significantly higher than that of hyperplastic tissues (P<0.05), and there was a weak correlation between them (P=0.002). In vitro, N‑Myc and FSCN1 were overexpressed in LNCaP and C4‑2 cell lines. The results revealed the promoting effect of N‑Myc and FSCN1 on malignant progression of PCa. In addition, the endogenous FSCN1 was knocked down in the C4‑2 cell line, and the results revealed that the silencing of FSCN1 enhanced the expression of N‑Myc and weakened the expression of the neuroendocrine marker CgA. Therefore, the present findings indicated that N‑Myc may promote the malignant process of PCa by regulating FSCN1 and FSCN1 may have a reverse regulatory effect on N‑Myc.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer Statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Chen Y, Sawyers CL and Scher HI: Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 8:440–448. 2008. View Article : Google Scholar : PubMed/NCBI
4	Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al: Integrative genomic profiling of human prostate cancer. Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
5	Zarour L and Alumkal J: Emerging therapies in Castrate-resistant prostate cancer. Curr Urol Rep. 11:152–158. 2010. View Article : Google Scholar : PubMed/NCBI
6	Wang HT, Yao YH, Li BG, Tang Y, Chang JW and Zhang J: Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: Factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol. 32:3383–3390. 2014. View Article : Google Scholar : PubMed/NCBI
7	Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, Hicks JL, Meeker AK, Bieberich CJ, De Marzo AM, et al: ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol. 24:820–828. 2011. View Article : Google Scholar : PubMed/NCBI
8	Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, Mosier S, Gocke CD, Epstein JI, Netto GJ, et al: Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res. 20:890–903. 2014. View Article : Google Scholar : PubMed/NCBI
9	Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, et al: Integrative clinical genomics of advanced prostate cancer. Cell. 161:1215–1228. 2015. View Article : Google Scholar : PubMed/NCBI
10	Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, et al: Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 22:298–305. 2016. View Article : Google Scholar : PubMed/NCBI
11	Dang CV: MYC on the path to cancer. Cell. 149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
12	Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT and Cohn SL: Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: A report from the Children's Oncology Group. J Clin Oncol. 26:913–918. 2008. View Article : Google Scholar : PubMed/NCBI
13	Massimino M, Biassoni V, Gandola L, Garrè ML, Gatta G, Giangaspero F, Poggi G and Rutkowski S: Childhood medulloblastoma. Crit Rev Oncol Hematol. 105:35–51. 2016. View Article : Google Scholar : PubMed/NCBI
14	Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, Pomeroy SL, Korshunov A, Lichter P, Taylor MD and Pfister SM: Medulloblastomics: The end of the beginning. Nat Rev Cancer. 12:818–834. 2012. View Article : Google Scholar : PubMed/NCBI
15	Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, Popov S, Bax DA, Carvalho D, Taylor KR, Vinci M, et al: Histone H3.3. Mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 3:512–519. 2013. View Article : Google Scholar : PubMed/NCBI
16	Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, et al: Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell. 21:601–613. 2012. View Article : Google Scholar : PubMed/NCBI
17	Fielitz K, Althoff K, De Preter K, Nonnekens J, Ohli J, Elges S, Hartmann W, Klöppel G, Knösel T, Schulte M, et al: Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells. Oncotarget. 7:74415–74426. 2016. View Article : Google Scholar : PubMed/NCBI
18	Yu Y, Xu L, Chang Y, Zeng T, Chen X, Wang A, Groth J, Foo WC, Liang C, Hu H and Huang J: N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway. Mol Cancer. 18:112019. View Article : Google Scholar : PubMed/NCBI
19	Hanker LC, Karn T, Holtrich U, Graeser M, Becker S, Reinhard J, Ruckhäberle E, Gevensleben H and Rody A: Prognostic impact of fascin-1 (FSCN1) in epithelial ovarian cancer. Anticancer Res. 33:371–377. 2013.PubMed/NCBI
20	Hashimoto Y, Skacel M and Adams JC: Roles of fascin in human carcinoma motility and signaling: Prospects for a novel biomarker? Int J Biochem Cell Biol. 37:1787–1804. 2005. View Article : Google Scholar : PubMed/NCBI
21	Scott KL, Nogueira C, Heffernan TP, van Doorn R, Dhakal S, Hanna JA, Min C, Jaskelioff M, Xiao Y, Wu CJ, et al: Proinvasion metastasis drivers in Early-stage melanoma are oncogenes. Cancer Cell. 20:92–103. 2011. View Article : Google Scholar : PubMed/NCBI
22	Li A, Morton JP, Ma Y, Karim SA, Zhou Y, Faller WJ, Woodham EF, Morris HT, Stevenson RP, Juin A, et al: Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Gastroenterology. 146:1386–1396.e17. 2014. View Article : Google Scholar : PubMed/NCBI
23	Barnawi R, Al-Khaldi S, Majed Sleiman G, Sarkar A, Al-Dhfyan A, Al-Mohanna F, Ghebeh H and Al-Alwan M: Fascin is critical for the maintenance of breast cancer stem cell pool predominantly via the activation of the notch Self-renewal pathway. Stem Cells. 34:2799–2813. 2016. View Article : Google Scholar : PubMed/NCBI
24	Sun J, He H, Xiong Y, Lu S, Shen J, Cheng A, Chang WC, Hou MF, Lancaster JM, Kim M and Yang S: Fascin protein is critical for transforming growth factor β Protein-induced invasion and filopodia formation in Spindle-shaped tumor cells. J Biol Chem. 286:38865–38875. 2011. View Article : Google Scholar : PubMed/NCBI
25	Snyder M, Huang XY and Zhang JJ: Signal transducers and activators of transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration. J Biol Chem. 286:38886–38893. 2011. View Article : Google Scholar : PubMed/NCBI
26	Zhao X, Gao S, Ren H, Sun W, Zhang H, Sun J, Yang S and Hao J: Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. Cancer Res. 74:2455–2464. 2014. View Article : Google Scholar : PubMed/NCBI
27	Sandelin A, Wasserman WW and Lenhard B: ConSite: Web-based prediction of regulatory elements using cross-species comparison. Nucleic Acids Res. 32:W249–W252. 2004. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, et al: Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1:487–495. 2011. View Article : Google Scholar : PubMed/NCBI
30	Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T, et al: N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell. 30:563–577. 2016. View Article : Google Scholar : PubMed/NCBI
31	Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, et al: N-myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells. Cancer Cell. 29:536–547. 2016. View Article : Google Scholar : PubMed/NCBI
32	Beltran H: The N-myc Oncogene: Maximizing its targets, regulation, and therapeutic potential. Mol Cancer Res. 12:815–822. 2014. View Article : Google Scholar : PubMed/NCBI
33	Adams JC: Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol. 16:590–596. 2004. View Article : Google Scholar : PubMed/NCBI
34	Lin S, Huang C, Gunda V, Sun J, Chellappan SP, Li Z, Izumi V, Fang B, Koomen J, Singh PK, et al: Fascin controls metastatic colonization and mitochondrial oxidative phosphorylation by remodeling mitochondrial actin filaments. Cell Rep. 28:2824–2836.e8. 2019. View Article : Google Scholar : PubMed/NCBI
35	Darnel AD, Behmoaram E, Vollmer RT, Corcos J, Bijian K, Sircar K, Su J, Jiao J, Alaoui-Jamali MA and Bismar TA: Fascin regulates prostate cancer cell invasionand is associated with metastasis and biochemical failurein prostate cancer. Cin Cancer Res. 15:1376–1383. 2009. View Article : Google Scholar